Evaluating dose- and time-dependent effects of vitamin c treatment on a Parkinsons disease fly model
Some clients tell me that, after taking a GLP-1, it is the first time *ever* in their life that they experienced the sensation of fullness
Attenuation of DIO in male PAR2-G37I mice was associated with no significant differences in food intake, water intake, locomotor activity, energy expenditure, and respiratory exchange ratio (Figure 3I and Supplemental Figure 5, DG)
Starting at 8 weeks of age, male and female cell GLP-1R WT ( Glp-1r cell+/+ [WT]) and KO ( Glp-1r cell/ [KO]) mice were fed a high-fat diet (HFD) for 6 weeks to produce an obese insulin-resistant phenotype (Figure 1A)
In response, some individuals explore microdosing as a way to improve tolerability, manage side effects, and create a more sustainable experience with GLP-1 therapy
and T.L